Home › Research › Down syndrome and Alzheimer's
Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181
Oeckl P, Wagemann O, Halbgebauer S, Anderl-Straub S, Nuebling G, Prix C, Loosli SV, Wlasich E et al.. Annals of neurology, 2022-04-12
Topic: Brain proteins, microglia and lab models
Plain-language summary
This exploratory case-control study investigates the synaptic marker beta-synuclein in serum and plasma pTau181 in adults with Down syndrome (DS) with (sDS, n = 14) and without (aDS, n = 47) clinical symptoms of Alzheimer disease (AD) as well as euploid controls (n = 23). Beta-synuclein was higher in aDS and more pronounced in sDS (p 0.90) to distinguish symptomatic from asymptomatic AD. The data indicate that synaptic alterations belong to the earliest AD-associated events in DS and highlight the value of serum beta-synuclein as a potential early marker of AD. ANN NEUROL 2022;92:6-10.
What this study adds
Evidence grade: Moderate
This is a case-control study of 14 participants. In this exploratory case-control study, serum beta-synuclein was higher in adults with Down syndrome and was more pronounced in those with clinical Alzheimer's disease symptoms. The authors highlight it as a potential early marker of Alzheimer's disease, which is about detection rather than treatment.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Oeckl, P., Wagemann, O., Halbgebauer, S., Anderl-Straub, S., Nuebling, G., Prix, C., et al. (2022). Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181. Annals of neurology. https://doi.org/10.1002/ana.26360
Vancouver
Oeckl P, Wagemann O, Halbgebauer S, Anderl-Straub S, Nuebling G, Prix C, et al. Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181. Annals of neurology. 2022. doi:10.1002/ana.26360. PMID: 35340050.
BibTeX
@article{oeckl2022-35340050,
author = {Oeckl, P. and Wagemann, O. and Halbgebauer, S. and Anderl-Straub, S. and Nuebling, G. and Prix, C. and Loosli, S. V. and Wlasich, E. and others},
title = {{Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181}},
journal = {Annals of neurology},
year = {2022},
doi = {10.1002/ana.26360},
pmid = {35340050},
url = {https://doi.org/10.1002/ana.26360}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The data indicate that synaptic alterations belong to the earliest AD-associated events in DS and highlight the value of serum beta-synuclein as a potential early marker of AD.
Why it matters
In this exploratory case-control study, serum beta-synuclein was higher in adults with Down syndrome and was more pronounced in those with clinical Alzheimer's disease symptoms. The authors highlight it as a potential early marker of Alzheimer's disease, which is about detection rather than treatment.
Study details
- Study designcase-control study
- Participants14
- Evidence strengthModerate
How this study scored 56/100
Published in a leading specialty journal, and it is a case-control study. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Annals of neurology) |
| Journal's citation record | 3 / 4 | Annals of Neurology: journal h-index 437 (OpenAlex, 2026-10-29) |
| Study design | 6 / 12 | A case-control study |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 14 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 20 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.3 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 2 / 6 | Cited 2.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 1 / 4 | Cited 11 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Markus Otto: h-index 95 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Ludwig-Maximilians-Universität München: institution h-index 1,224 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35340050) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.